AI generated summary of Pubmed citation/abstract with PMID 38093366

https://pubmed.ncbi.nlm.nih.gov/38093366

The ATHENEA trial found that NeuroEPO plus, a recombinant human erythropoietin, improved cognitive evaluation in individuals with mild-to-moderate Alzheimer’s disease clinical syndrome over 48 weeks, with a very good safety profile.